Congress Materials – Congress of Clinical Rheumatology (CCR West 2024)
2024 Congress of Clinical Rheumatology | Sep 26-29 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for Treating Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris, Jerry Bagel, Yu-Huei Huang, Andrew Pink, Stephen K. Tyring, Georgios Kokolakis, Amy M. DeLozier, Shu Li, Yaung-Kaung Shen, Jonathan Shelton, Takayuki Ota, Robert Bissonnette
Associations Between Clinical Characteristics and Screening MRI Findings in Biologic-naïve PsA Patients with MRI-confirmed Axial Involvement: STAR Study Exploratory Analysis
Xenofon Baraliakos, Paul Bird, Atul Deodhar, Dafna D. Gladman, Philip S. Helliwell, Denis Poddubnyy, Arthur Kavanaugh, Mikkel Østergaard, Enrique R. Soriano, Lai‑Shan Tam, Soumya D. Chakravarty, Evan Leibowitz, Cinty Gong, Stephen Xu, Thomas Fuerst, Nadeem Saeed, Robert Landewé, Philip J. Mease
Comparing On-Label Treatment Persistence in Real-World Patients With Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous IL-17A Inhibitors
Philip J. Mease, Ruizhi Zhao, Shannon Ferrante, Natalie J. Shiff, Donna Febres, Soumya D. Chakravarty, Jessica Walsh
Guselkumab Effect on cDAPSA and Its Association with Long-Term Radiographic Progression in Moderately-Highly Active Psoriatic Arthritis
Philip Mease, Alice B. Gottlieb, Iain B. McInnes, Natalie J. Shiff, Natalie Masis, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Proton Rahman
Efficacy and Safety of Guselkumab in Patients With Moderately to Severely Active Crohn’s Disease: Results of the GALAXI 2 & 3 Phase 3 Studies
Remo Panaccione, Silvio Danese, Brian Feagan, Geert D’Haens, Anita Afzali, Walter Reinisch, Julián Panés, David T. Rubin, Jane Andrews, Tadakazu Hisamatsu, Natalie A. Terry, Leonardo Salese, Rian Van Rampelbergh, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Kitty Yuen Yi Wan, Hazeline Hakansson, Jacqueline Yee, Bruce E. Sands
Efficacy and Safety of Nipocalimab in Primary Sjogren’s Disease: Results From a Phase 2, Randomized, Double-blind DAHLIAS Study
Jacques Eric Gottenberg, Kathy Sivils, Kim Campbell, Jada Idokogi, Kim Lo, Sophia G. Liva, Jonathan Shelton, Harman Dhatt, Jonathan J. Hubbard, Ghaith Noaiseh
Efficacy of Guselkumab in Bionaïve Psoriatic Arthritis Patients with Severe Disease Activity: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Christopher T. Ritchlin, Ennio Lubrano, Maria Sole Chimenti, Evan Leibowitz, Mohamed Sharaf, Natalie Masis, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Atul Deodhar
Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients With Psoriatic Disease and Systemic Inflammation Associated With CV Risk
Joseph F. Merola, Alexis Ogdie, Arthur Kavanaugh, Evan Leibowitz, Emmanouil Rampakakis, Francois Nantel, Frederic Lavie, Katelyn Rowland, Enrique R. Soriano
On-label persistence through 24 months in patients with psoriatic arthritis using guselkumab or subcutaneous interleukin-17A inhibitors
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Linda Hou, Shikha Singla, Joseph F Merola
Efficacy and Safety of Guselkumab as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 3 QUASAR Maintenance Study
David T. Rubin, Jessica R. Allegretti, Julián Panés, Nicole Shipitofsky, Shadi Yarandi, Kuan-Hsiang G. Huang, Matthew Germinaro, Rebbecca Wilson, Hongyan Zhang, Hazeline Hakansson, Brian G. Feagan, Tadakazu Hisamatsu, Gary R. Lichtenstein, Brian Bressler, Laurent Peyrin-Biroulet, Bruce E. Sands, Axel Dignass
On-label persistence through 24 months among patients with psoriatic arthritis initiating guselkumab or subcutaneous TNF inhibitors
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D Chakravarty, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Linda Hou, Shikha Singla, Joseph F Merola
VISIBLE: Guselkumab Impact on Psoriatic Arthritis at Week 16 in Participants With Moderate-to-Severe Psoriasis Across All Skin Tones
A. B. Gottlieb, A. McMichael, T. Bhutani, O. Choi, T. Alkousakis, J. Jeyarajah, D. Febres, O. Adelakun, S. D. Chakravarty, D. Chan, J. F. Merola
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.